Puchar A, Luton D, Koskas M
Obstetrics and Gynecology, Bichat University Hospital, Paris Diderot University, Paris, France.
Drugs Today (Barc). 2015 Nov;51(11):661-7. doi: 10.1358/dot.2015.51.11.2413469.
Uterine fibroids are the most common benign uterine tumors in women of reproductive age. Although most women are asymptomatic (80%), fibroids, according to their type and location, can cause several symptoms and impact quality of life. To date, no medical treatment is able to eliminate fibroids. Ulipristal acetate (UPA) is an orally active synthetic selective progesterone receptor modulator (SPRM) characterized by a tissue-specific progesterone antagonist effect that reduces the proliferation of leiomyoma cells and induces apoptosis. It was licensed in Europe for preoperative fibroid treatment in 2012. Its pharmacological and pharmacodynamic characteristics, its efficacy and good tolerance make UPA a new important tool in the management of uterine fibroids.
子宫肌瘤是育龄期女性最常见的良性子宫肿瘤。尽管大多数女性无症状（80%），但根据肌瘤的类型和位置，可能会引发多种症状并影响生活质量。迄今为止，尚无药物治疗能够消除子宫肌瘤。醋酸乌利司他（UPA）是一种口服活性合成选择性孕激素受体调节剂（SPRM），具有组织特异性孕激素拮抗剂作用，可减少平滑肌瘤细胞增殖并诱导细胞凋亡。2012年在欧洲获批用于术前子宫肌瘤治疗。其药理和药效学特性、疗效及良好的耐受性使UPA成为子宫肌瘤管理中的一种重要新工具。
